Ono Begins Trials for New Hepatocellular Carcinoma Therapy
This article was originally published in PharmAsia News
Executive Summary
Ono Pharmaceuticals announced their July 2 submission of Phase 1 trial documentation for the hepatocellular carcinoma treatment peptid vaccine ONO-7268MX1, developed by Oncotherapy Science.